Geode Capital Management LLC boosted its stake in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 10.1% during the first quarter, Holdings Channel reports. The firm owned 1,002,784 shares of the biopharmaceutical company’s stock after buying an additional 92,043 shares during the period. Geode Capital Management LLC’s holdings in Achillion Pharmaceuticals were worth $4,221,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in Achillion Pharmaceuticals during the fourth quarter valued at about $4,623,000. Vanguard Group Inc. raised its stake in Achillion Pharmaceuticals by 7.2% in the first quarter. Vanguard Group Inc. now owns 9,585,823 shares of the biopharmaceutical company’s stock valued at $40,357,000 after buying an additional 646,415 shares during the period. HealthInvest Partners AB purchased a new stake in Achillion Pharmaceuticals during the first quarter valued at about $2,096,000. Stifel Financial Corp purchased a new stake in Achillion Pharmaceuticals during the first quarter valued at about $1,744,000. Finally, Teachers Advisors LLC raised its stake in Achillion Pharmaceuticals by 42.9% in the first quarter. Teachers Advisors LLC now owns 1,347,858 shares of the biopharmaceutical company’s stock valued at $5,674,000 after buying an additional 404,317 shares during the period. Hedge funds and other institutional investors own 70.70% of the company’s stock.

Shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) traded up 1.60% on Wednesday, hitting $5.08. 265,254 shares of the stock were exchanged. The company’s 50 day moving average is $4.42 and its 200-day moving average is $4.14. The stock’s market cap is $694.75 million. Achillion Pharmaceuticals, Inc. has a 52-week low of $3.15 and a 52-week high of $9.49.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.16). During the same quarter last year, the firm posted ($0.14) EPS. Analysts predict that Achillion Pharmaceuticals, Inc. will post ($0.63) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first posted by Watch List News and is the property of of Watch List News. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.watchlistnews.com/geode-capital-management-llc-has-4-22-million-stake-in-achillion-pharmaceuticals-inc-achn/1494909.html.

A number of equities research analysts recently weighed in on ACHN shares. Robert W. Baird lifted their price objective on shares of Achillion Pharmaceuticals from $5.00 to $10.00 and gave the company an “outperform” rating in a report on Monday, April 24th. Leerink Swann upgraded shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $4.00 to $6.00 in a report on Thursday, May 18th. Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. BidaskClub lowered shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 25th. Finally, Jefferies Group LLC reiterated a “hold” rating on shares of Achillion Pharmaceuticals in a report on Wednesday, April 26th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $8.25.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.